AKBA
Akebia Therapeutics, Inc.
AKBA trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over AKBA overall, supported by stronger fundamentals and lower modeled downside.
AKBA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Stable | |
| Strong |
AKBA's balance sheet is currently strong, and its cash flow is stable, but its revenue and profitability are weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AKBA PE Valuation
AKBA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AKBA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect AKBA's losses to grow, with revenue declining. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over AKBA on the outlook, with more favorable earnings and revenue expectations.
AKBA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.16 | -$0.09 |
| Q2 2026 | -$0.11 | +$0.06 |
| Q1 2026 | -$0.08 | +$0.13 |
| Q4 2025 | -$0.02 | +$0.31 |
| Q3 2025 | -$0.07 | +$0.15 |
| Q2 2025 | -$0.17 | +$0.03 |
| Q1 2025 | -$0.21 | +$0.01 |
| Q4 2024 | -$0.33 | -$0.06 |
AKBA lost $0.16 per share over the past year, and its loss has widened in each of the last three quarters.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AKBA on earnings quality, reporting a profit while its opponent remains loss making.
AKBA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $36.9M | -37% |
| Q2 2026 | $49.1M | -21% |
| Q1 2026 | $53.5M | -6.6% |
| Q4 2025 | $57.6M | +24% |
| Q3 2025 | $58.8M | +57% |
| Q2 2025 | $62.5M | +43% |
| Q1 2025 | $57.3M | +76% |
| Q4 2024 | $46.5M | -17% |
AKBA's revenue has slid since its 2022 peak: $37M last quarter, down 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -31% | -39 points |
| Q2 2026 | -13% | -35 points |
| Q1 2026 | -8.8% | -32 points |
| Q4 2025 | -15% | +16 points |
| Q3 2025 | 7.6% | +41 points |
| Q2 2025 | 23% | +43 points |
| Q1 2025 | 24% | +69 points |
| Q4 2024 | -31% | -33 points |
AKBA's operating margin was −31% last quarter, down 39 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AKBA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AKBA on profitability, with a higher operating margin.
AKBA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.6M | -94% |
| Q2 2026 | $2.4M | -89% |
| Q1 2026 | -$21.3M | -$7.7M |
| Q4 2025 | $31.1M | +$35.5M |
| Q3 2025 | $28M | +$34.7M |
| Q1 2025 | -$13.6M | +$5.8M |
| Q4 2024 | -$4.5M | -$2.2M |
| Q3 2024 | -$6.7M | +$470K |
AKBA has burned cash in most quarters: $14M over the past year, down 57% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AKBA on cash flow, with more consistent year-over-year improvement.
AKBA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +7.3M shares |
| 1 year | +0.9% | +2.5M shares |
| 3 years | +47% | +88.6M shares |
| 5 years | +59% | +103M shares |
| Available history | +132% | +158M shares |
AKBA has 277M diluted shares, up 0.9% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AKBA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AKBA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -17.3x | Net Cash |
| Q4 2025 | -5.5x | Net Cash |
| Q3 2025 | -4.2x | Net Cash |
| Q2 2025 | -4.5x | Net Cash |
| Q1 2025 | -10.5x | Net Cash |
| Q3 2024 | 1.6x | Healthy |
AKBA has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AKBA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 14.7 | Oversold |
AKBA's weekly RSI is 33 (neutral) and its Stochastic is 15 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AKBA PE vs Healthcare Sector
AKBA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AKBA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.68 | 26% below |
| 20 week MA | $0.92 | 46% below |
| 50 week MA | $1.16 | 57% below |
| 100 week MA | $1.88 | 73% below |
| 200 week MA | $1.56 | 68% below |
AKBA is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AKBA on trend strength, trading above more of its moving averages.
AKBA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.52 | $2.92 | -55% |
| 2021 | $2.92 | $2.53 | -13% |
| 2022 | $2.53 | $0.43 | -83% |
| 2023 | $0.43 | $1.24 | +188% |
| 2024 | $1.24 | $1.95 | +57% |
| 2025 | $1.95 | $1.66 | -15% |
| 2026 YTD | $1.66 | $0.50 | -70% |
AKBA's yearly returns have swung widely, from +188% in 2023 to −83% in 2022. It's down 70% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AKBA on returns for 2026, with the stronger performance.